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Available online 14 February 2018We have generated a human iPSC line, IISHDOi002-A, from commercial primary normal human dermal ﬁbro-
blasts belonging to an Africanmitochondrial haplogroup (L3), andwith a 46, XY/47, XYYmosaicism. For this pur-
pose, reprogramming factors Oct3/4, Sox2, Klf4 and cMyc were delivered using a non-integrative methodology
that involves the use of Sendai virus.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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406329 1.Resource utility
Functional studies using iPSCs generated from patients with
mitochondrial diseases (MD) require the use of the most appropriate
controls. An isogenic control is not always possible. The availability of
the iPSC line, IISHDOi002-A, will be very useful for functional studies
of MD patients belonging to a L3 haplogroup.
Resource details
The establishment of a human iPSC line, IISHDOi002-A, was per-
formed using non-integrative methodology that involves the use of
Sendai viruses containing the reprogramming factors Oct3/4, Sox2,
Klf4 and c-Myc (Takahashi et al., 2007). For this purpose, commer-
cially available ﬁbroblasts from a healthy neonatal donor were ac-
quired in Lonza (CC2509). Subsequently, mitochondrial haplogroup
determination was carried out in the IISHDOi002-A line and in the
original ﬁbroblasts by PCR ampliﬁcation of mitochondrial DNA
(mtDNA) regions containing the nucleotides positions that deﬁne
the L3 haplogroup (m.10400 and m.3594) followed by direct se-
quencing of the generated amplicons (Table 1). The identiﬁcation
of the mtDNA nucleotide variations m.10400C and m.3594 T showed
that ﬁbroblasts and the generated iPSC line IISHDOi002-A belong tottp://creativecommons.org/licenses/by-nc-nd/4.0/).
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iPSC colonies displayed a typical ES-like colony morphology and
growth behavior (Fig. 1B) and they stained positive for alkaline
phosphatase (AP) activity (Fig. 1C). The endogenous expression of
the pluripotency associated transcription factors OCT4, SOX2, KLF4,
NANOG, CRIPTO and REX1 was evaluated by quantitative real time
polymerase chain reaction (qPCR) (Fig. 1D). Immunoﬂuorescence
analysis revealed expression of the pluripotency-associated tran-
scription factors OCT4, SOX2 and NANOG, and surface markers
SSEA3, SSEA4, TRA1-81 and TRA1-60 (Fig. 1E). We also conﬁrmed
the clearance of the vectors and the exogenous reprogramming fac-
tor genes by RT-PCR after nine culture passages (Fig. 1F). The iPSC
line has been adapted to feeder-free culture conditions and a karyo-
type analysis after more than 20 culture passages has been carried
out. This analysis displayed a 46, XY (28)/47, XYY (2) mosaicism in
the iPSC line (Fig. 1G). We also conﬁrmed the presence of abnormal
cells at 4–4.5% in two different aliquots of the original ﬁbroblasts
by FISH analysis of 200 interphase cells [nuc ish (DYZ1x2, DYZ1x1)
[9/200] (Fig. 1G). These data suggest that this mosaicism could be a
causal ﬁnding in the ﬁbroblasts and have a somatic origin. The level
of mosaicism in the ﬁbroblasts has been maintained around 4.5%
during more than 30 passages. In any case, males with an extra
copy of the Y chromosome typically have no unusual physical fea-
tures although they could have fertility problems. Regarding the
case reported here, the identiﬁed mosaicism, to our knowledge, is
not related with any noteworthy phenotypic trait present in the car-
rier. We also veriﬁed by DNA ﬁngerprinting analysis that the line
IISHDOi002-A was derived from the patient's ﬁbroblasts (Supple-
mentary Fig. S1). In addition, the line was conﬁrmed by PCR analysis
to be mycoplasma-negative (Fig. 1H). Finally, the capacity of the
IISHDOi002-A iPSC line to differentiate into the three germ layers
(endoderm, mesoderm and ectoderm) was evaluated in vitro using
an embryoid body based assay (Fig. 1I).
Materials and methods
iPSCs generation
Healthy human neonatal ﬁbroblasts (Lonza, CC2509) were
reprogrammed using the CytoTune-iPS 2.0 Sendai reprogramming kit
following the instructions of the manufacturer. IISHDOi002-A was ex-
panded as described in Galera et al., 2016.Table 1
Characterization and validation.
Classiﬁcation Test Result
Morphology Photography Normal
Phenotype Qualitative analysis: immunocytochemistry Positive for t
OCT4, NANO
Qualitative analysis: alkaline phosphatase
activity
Positive
Quantitative analysis: gene expression
(qPCR)
Positive for t
Genotype Karyotype (G-banding) and resolution 46, XY (28)/
Resolution 4
Identity Microsatellite PCR (mPCR) N/A
STR analysis 8 loci, all ma
VWA, amelo
Mutation analysis (if
applicable)
Sequencing N/A
Southern Blot OR WGS N/A
Haplogroup analysis Sequencing Conﬁrmation
Microbiology and virology Mycoplasma Negative
Sendai virus silencing Virus silence
Differentiation potential Embryoid body formation and directed
differentiation
Positive for:
alpha-fetopr
Donor screening (optional) HIV 1+2 Hepatitis B, Hepatitis C N/A
Genotype additional info
(optional)
Blood group genotyping N/A
HLA tissue typing N/AAP analysis
The iPSC line was seeded on a feeder layer plate. After one week, di-
rect AP activity was determined using the AP blue membrane substrate
solution kit (Sigma, AB0300).
Mitochondrial haplogroup
DNAs from ﬁbroblasts and IISHDOi002-Awere haplogrouped by PCR
and direct sequencing, using the primers described in Table 2. The
mtDNA nucleotides, m.10400C and m.3594 T, deﬁning the African
haplogroup L3, have been veriﬁed.
qPCR analysis
Total mRNA was isolated using TRIZOL and cDNA using the
Quantitect RT cDNA synthesis kit. The expression of the endogenous
pluripotency associated genes (OCT4, SOX2, KLF4, NANOG, CRIPTO and
REX1) was quantiﬁed by qPCR. Primers are listed in Table 2 (Aasen
et al., 2008). All the expression values were normalized to the GAPDH
gene. Plots are representative of at least three independent
experiments.
Karyotype and FISH
Cells were treated with 10 μg/mL of Colcemid (Gibco) for 90 min at
37 °C, trypsinized, treatedwith KCl 0.075M, and ﬁxedwith Carnoy's ﬁx-
ative for karyotype analysis and ﬁxed three times in methanol/acetic
acid (3:1) for FISH. Cells were then dropped on a microscope glass
slide and dried. Metaphase cells were G banded using Wright staining.
At least 30 metaphases were karyotyped. For FISH, CEP probe for chro-
mosomes Y (DYZ1) and slideswere denatured at 72 °C for 2min and in-
cubated at 37 °C (16 h) for hybridization. Slides were washed in SSC
with 0.1% Tween 20. Coverslips were mounted on the slides with
DAPI. 200 interphase cells were analyzed with a Nikon ﬂuorescent mi-
croscope. Digital images were acquired with a monochrome CCD cam-
era linked to Metasystem software.
Immunoﬂuorescence analysis
Cells were grown on 0.1% gelatin-coated 35mm culture plates, ﬁxed
with 4% paraformaldehyde 30min at RT and permeabilized using TBS+Data
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Fig. 1.Molecular and functional characterization of the IISHDOi002-A iPSC line.
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cells were incubated in TBS++ (3% donkey serum, 0.3% Triton X-100
in TBS) for 2 h at RT. Primary antibodies were applied overnight at 4
°C. Secondary antibodies, 2 h at RT. Nuclei were stained with DAPI
(Sigma, 28718-90-3). All the antibodies are listed in Table 2.
In vitro differentiation assay
The in vitro pluripotency capacity of the line IISHDOi002-A was
tested by spontaneous embryoid body differentiation. The protocol we
have used has been described in detail by Galera et al. (2016).
DNA ﬁngerprinting
The markers D13S317, D7S820, VWA, D8S1179, D21S11, D19S433,
D2S1338 and amelogenin for sex determination were ampliﬁed by
PCR and analyzed by ABI PRISM 3100 Genetic analyzer and Peak Scan-
ner v3.5 (Thermoﬁsher) (Table 2).Table 2
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-cytometry
Antibody
Pluripotency markers Mouse anti-TRA-1-81
Mouse anti-TRA-1-60
Rabbit anti-SOX2
Mouse anti-SSEA4
Rat anti-SSEA3
Goat anti-NANOG
Mouse anti-OCT4
Differentiation
markers
Mouse anti-β tubulin isotype III
Mouse anti-AFP
Mouse anti-SMA
Secondary antibodies Cy™2-conjugated AfﬁniPure Donkey Anti-Goat IgG (H+L)
Cy™2-conjugated AfﬁniPure Goat Anti-Mouse IgG, Fcγ Subclass 2
speciﬁc
Cy™2-conjugated AfﬁniPure Goat Anti-Rabbit IgG (H+L)
Cy™3-conjugated AfﬁniPure Goat Anti-Rat IgM, μ chain speciﬁc
Cy™3-conjugated AfﬁniPure Goat Anti-Mouse IgG, Fcγ Subclass 3
speciﬁc
Cy™3-conjugated AfﬁniPure Donkey Anti-Mouse IgM, μ chain spe
Goat anti-mouse IgG (H+L), Alexa Fluor 488
Primers
Target
Pluripotency markers (qPCR) Endo-KLF4
Endo-OCT4
Endo-SOX2
REX1
CRIPTO
NANOG
House-Keeping Genes (qPCR) GAPDH
Haplogroup analysis mtDNA region: from m.9977 to m.10858
mtDNA region: from m.3150 to m.3980
Virus silencing SeV
KOS
Klf4
c-Myc
STR analysis D2S1338
D7S820
D8S1179
D13S317
D19S433
D21S11
VWA
Amelogenin
Mycoplasma detection GPO-3/MGSOMycoplasma detection
Mycoplasma detection was performed by PCR (primers speciﬁed in
Table 2) using 1 mL of the cell culture supernatant (3 days culture at
90% conﬂuence). The 300 bp band represents that the sample is positive
for mycoplasma. The band at 570 bp is an internal control to discard the
inhibition of the polymerase.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2018.02.009.
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Forward/reverse primer (5′-3′)
AGCCTAAATGATGGTGCTTGGT/TTGAAAACTTTGGCTTCCTTGTT
GGGTTTTTGGGATTAAGTTCTTCA/GCCCCCACCCTTTGTGTT
CAAAAATGGCCATGCAGGTT/AGTTGGGATCGAACAAAAGCTATT
CCTGCAGGCGGAAATAGAAC/GCACACATAGCCATCACATAAGG
CGGAACTGTGAGCACGATGT/GGGCAGCCAGGTGTCATG
ACAACTGGCCGAAGAATAGCA/GGTTCCCAGTCGGGTTCAC
GCACCGTCAAGGCTGAGAAC/AGGGATCTCGCTCCTGGAA
TCTCCATCTATTGATGAGGGTCT/CAACCACCCACAGCCTAATT
TACTTCACAAAGCGCCTTCC/CCCTTCGCCCTATTCTTCAT
GGATCACTAGGTGATATCGAGC/ACCAGACAAGAGTTTAAGAGATATGTATC
ATGCACCGCTACGACGTGAGCGC/ACCTTGACAATCCTGATGTGG
TTCCTGCATGCCAGAGGAGCCC/AATGTATCGAAGGTGCTCAA
TAACTGACTAGCAGGCTTGTCG/TCCACATACAGTCCTGGATGATGATG
[6-FAM] CCAGTGGATTTGGAAACAGA/ACCTAGCATGGTACCTGCAG
[6-FAM] TGTCATAGTTTAGAACGAACTAACG/CTGAGGTATCAAAAACTCAGAGG
[6-FAM] TTTTTGTATTTCATGTGTACATTCG/CGTAGCTATAATTAGTTCATTTTCA
[6-FAM] ACAGAAGTCTGGGATGTGGA/GCCCAAAAAGACAGACAGAA
[6-FAM] CCTGGGCAACAGAATAAGAT/TAGGTTTTTAAGGAACAGGTGG
[6-FAM] GTGAGTCAATTCCCCAAG/GTTGTATTAGTCAATGTTCTCC
[6-FAM] CCCTAGTGGATGATAAGAATAATC/GGACAGATGATAAATACATAGGATGGATGG
[6-FAM] CCCTGGGCTCTGTAAAGAATAGTG/ATCAGAGCTTAAACTGGGAAGCTG
GGGAGCAAACAGGATTAGATACCCT/TGCACCATCTGTCACTCTGTTAACCTC
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